Shengyong Yang
Sichuan University(CN)State Key Laboratory of Biotherapy
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Angiogenesis and VEGF in Cancer, Immunotherapy and Immune Responses
Most-Cited Works
- → Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models(2017)71 cited
- → Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer(2019)43 cited
- → Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo(2012)33 cited
- → SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML(2015)32 cited
- → Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis(2019)32 cited
- → Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer(2015)27 cited
- → SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth <i>in Vivo</i>(2011)25 cited
- → Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control(2020)21 cited
- → Preparative purification of anti-tumor derivatives of honokiol by high-speed counter-current chromatography(2007)20 cited
- → Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants(2017)19 cited